Zilebesiran is an antisense rnai oligonucleotide commercialized by Alnylam Pharmaceuticals, with a leading Phase II program in Hypertension. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Zilebesiran’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Zilebesiran is expected to reach an annual total of $119 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Zilebesiran Overview

Zilebesiran sodium (ALNAGT-01) is under development for hypertension. The drug candidate is administered subcutaneously. The drug candidate is an RNAi therapeutic targeting angiotensinogen (AGT) and developed based on enhanced stabilization chemistry (ESC)-GalNAc-conjugate delivery platform technology. It was also under development for the treatment of pre-eclampsia.

Alnylam Pharmaceuticals Overview

Alnylam Pharmaceuticals (Alnylam) is a biopharmaceutical company, which discovers, develops and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro, which is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline of investigational RNAi drugs in the areas of genetic medicines, hepatic infectious, cardio-metabolic, and central nervous system (CNS) diseases. Its late-stage product candidates include vutrisiran for ATTR amyloidosis, inclisiran for hypercholesterolemia, fitusiran for hemophilia and rare bleeding disorders, and lumasiran for severe PH1. The company operates subsidiaries in North America, Europe and Asia-Pacific. Alnylam is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$844.3 million for the fiscal year ended December 2021 (FY2021), an increase of 71.3% over FY2020. The operating loss of the company was US$708.7 million in FY2021, compared to an operating loss of US$828.4 million in FY2020. The net loss of the company was US$852.8 million in FY2021, compared to a net loss of US$858.3 million in FY2020. The company reported revenues of US$264.3 million for the third quarter ended September 2022, an increase of 17.6% over the previous quarter.

For a complete picture of Zilebesiran’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.